Monday, May 15, 2023 10:33:38 PM
HyFi is drawing capital primarily from banks, life insurance, pension funds, endowments, hedge funds and sovereign funds. Our focus is on the large capital pool in the American Bond Market ($46T) and the private debt (promissory note market ($1T))
Our structured finance investment banking consortium (the institutions underwriting or placing our deals) include but are not limited to the following:
1. Leading US Bank with an investment grade credit rating that in 2022 raised over $400 billion in the debt capital markets via over 500 transactions and also raised over $60 billion in equity capital markets via over 100 deals.
2. Proven issuer of bonds with $10B in transactions to date – a specialist in infrastructure issuances
3. US Broker dealer with $7B in transaction to date – with a wide range of solutions including lease lines of credit
4. Private debt placement (promissory notes) capital markets company with $4B in transactions to date
5. One of the largest equipment financing companies in the industry
HyFi's Collaborative Financing
HyFi is cultivating relationships with leading international financial institutions such as AfDB, IFC/World Bank, IFAD, Afreximbank & EIB. The purpose of these relationships it to collaborate to create the right conditions for underwriting financing in regions which are disadvantaged from a credit perspective, yet a viable project opportunity exists.
With our structured finance offering you can secure a loan or a lease, of a hybrid solution and enjoy up to 3 years deferral of any principal or interest repayment, this will give your project a change to get into revenue before facing any repayment obligation.
Competitive interest rates are offered and there is no equity investment component needed.
Selling equity is an option, not a requirement. Selling equity later as your project matures is a key benefit that HyFi’s 100-125% structured financing solution provides.
https://www.hyfi-corp.com/structured-finance/
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM